Organogenesis Holdings Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ORGO$0.94+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net revenue | $109,976 | $107,642 |
| Cost of goods sold | 28,696 | 26,607 |
| Gross profit | 81,280 | 81,035 |
| Operating expenses: | ||
| Selling, general and administrative | 72,322 | 73,834 |
| Research and development | 12,810 | 11,202 |
| Total operating expenses | 85,132 | 85,036 |
| Loss from operations | (3,852) | (4,001) |
| Other expense, net: | ||
| Interest expense, net | (514) | (649) |
| Other income, net | 23 | 23 |
| Total other expense, net | (491) | (626) |
| Net loss before income taxes | (4,343) | (4,627) |
| Income tax benefit | 2,243 | 1,658 |
| Net loss and comprehensive loss | $(2,100) | $(2,969) |
| Net loss, per share: | ||
| Basic and diluted | $(0.02) | $(0.02) |
| Weighted-average common shares outstanding | ||
| Basic and diluted | 131,861,772 | 131,083,841 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.